![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CADENCE PHARMACEUTICALS ANNOUNCES $25 MILLION FINANCING
CADENCE PHARMACEUTICALS ANNOUNCES $25 MILLION FINANCING
October 11, 2005
Cadence Pharmaceuticals, Inc., a hospital-focused specialty pharmaceutical company, today announced the completion of a $25 million Series A preferred stock financing. Domain Associates led the round which included ProQuest Investments, BB Biotech
Ventures, CDIB BioScience Venture Management, Windamere Venture Partners, and private investors.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-11-2005/0004165321&EDATE=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct